Document Detail


Antiproliferative effect of the jararhagin toxin on B16F10 murine melanoma.
MedLine Citation:
PMID:  25407317     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Malignant melanoma is a less common but highly dangerous form of skin cancer; it starts in the melanocytes cells found in the outer layer of the skin. Jararhagin toxin, a metalloproteinase isolated from Bothrops jararaca snake venom acts upon several biological processes, as inflammation, pain, platelet aggregation, proliferation and apoptosis, though not yet approved for use, may one day be employed to treat tumors.
METHODS: B16F10 murine melanoma cells were treated with jararhagin (jara), a disintegrin-like metalloproteinase isolated from Bothrops jararaca snake venom, and jari (catalytic domain inactivated with 1,10-phenanthroline). Viability and adhesion cells were evaluated by MTT assay. The expression of caspase-3 active, phases of the cell cycle and apoptosis were assessed by flow cytometry. We analyze in vivo the effects of jararhagin on melanoma growth, apoptosis and metastasis.
RESULTS: The tumor cells acquired round shapes, lost cytoplasmic expansions, formed clusters in suspension and decreased viability. Jari was almost 20 times more potent toxin than jara based on IC50 values and on morphological changes of the cells, also observed by scanning electron microscopy. Flow cytometry analysis showed 48.3% decrease in the proliferation rate of cells and 47.2% increase in apoptosis (jara) and necrosis (jari), following 1.2 muM jara and 0.1 muM jari treatments. Caspase-3 activity was increased whereas G0/G1 cell cycle phase was on the decline. Proliferative rate was assessed by staining with 5,6-carboxyfluoresceindiacetate succinimidyl ester, showing a significant decrease in proliferation at all concentrations of both toxins.
CONCLUSIONS: In vivo treatment of the toxins was observed reduction in the incidence of nodules, and metastasis and antiproliferative inhibition capacity. This data strengthens the potential use jararhagin as an anti-neoplastic drug.
Authors:
Durvanei Augusto Maria; Manuela Garcia da Silva; Mario Cesar Correia; Itamar Romano Ruiz
Related Documents :
11029417 - Swarming of pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires ...
17652307 - Chemotaxis: navigating by multiple signaling pathways.
6592607 - Ca2+ causes active contraction of bile canaliculi: direct evidence from microinjection ...
10753747 - Genetic deletion of the pten tumor suppressor gene promotes cell motility by activation...
23767627 - Control of centrifugally driven fingering in a tapered hele-shaw cell.
10082327 - Cytotoxic effect of paraquat on rat c6 glioma cells: evidence for the possibility of no...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-18
Journal Detail:
Title:  BMC complementary and alternative medicine     Volume:  14     ISSN:  1472-6882     ISO Abbreviation:  BMC Complement Altern Med     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-19     Completed Date:  -     Revised Date:  2014-11-20    
Medline Journal Info:
Nlm Unique ID:  101088661     Medline TA:  BMC Complement Altern Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  446     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  En bloc resection and bone graft: does it alter the natural history of monostotic expansile fibrous ...
Next Document:  A bio-catalytically driven Janus mesoporous silica cluster motor with magnetic guidance.